Episode 1: Taking Stock of the Bio/Pharma M&A Landscape

Now that the latest J.P. Morgan Healthcare Conference has closed its doors and the dust has started to settle on the discussions and sentiments realized from the event, the global bio/pharma industry is optimistic for M&A momentum in 2026. However, while there is positivity around the dealmaking table for the near future, there is also a clear indicator that potential deals will also be done in a disciplined manner and will include assets that are execution ready. To find out more about the prospects for the bio/pharma M&A landscape in 2026 and beyond, The Pharma Navigator sat down with a panel of experts, which comprised: Dr. Lubor Gaal, Chief Financial Officer and Head of Business Development at Circio Holding, and Chief Business Officer at MitoRx; Megha Sinha, Managing Partner and CEO of Kamet Consulting Group; and Ali Pashazadeh, Founder, Chairman, and CEO of Treehill Partners. Music from #Uppbeat (free for Creators!): https://uppbeat.io/t/tatami/frisbee License code: O9DQHCKSKLL6MYMU